Benchmark Upgrades McGraw-Hill (MHP) to Buy; Attractive Valuation and Break Up Value
Get Alerts MHP Hot Sheet
Price: $55.93 +0.59%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
Benchmark upgraded McGraw-Hill (NYSE: MHP) from Hold to Buy with a price target of $53.00.
Analyst, Edward J. Atorino, said, "Upgrades to reflect strong growth prospects of McGraw-Hill‘s financial operations and the stock’s discount to estimated break up value following separation of McGraw-Hill Education from McGraw Hill’s financial operations."
"For 2013, we project total revenues of $6.9 billion, up 7%, led by growth at S&P Ratings and Capital IQ with some improvement in Education and further growth at Commodities and Commercial. We project EPS to advance to $3.71, up 11%."
For an analyst ratings summary and ratings history on McGraw-Hill click here. For more ratings news on McGraw-Hill click here.
Shares of McGraw-Hill closed at $43.89 yesterday.
Analyst, Edward J. Atorino, said, "Upgrades to reflect strong growth prospects of McGraw-Hill‘s financial operations and the stock’s discount to estimated break up value following separation of McGraw-Hill Education from McGraw Hill’s financial operations."
"For 2013, we project total revenues of $6.9 billion, up 7%, led by growth at S&P Ratings and Capital IQ with some improvement in Education and further growth at Commodities and Commercial. We project EPS to advance to $3.71, up 11%."
For an analyst ratings summary and ratings history on McGraw-Hill click here. For more ratings news on McGraw-Hill click here.
Shares of McGraw-Hill closed at $43.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Upgrades Lovisa Holdings Ltd (LOV:AU) to Buy
- Barclays Upgrades GEA Group AG (G1A:GR) (GEAGY) to Overweight
- Wolfe Research Upgrades Kymera Therapeutics (KYMR) to Outperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share